Neuromuscular and Neurodegenerative Diseases: Towards Personalized Medicine, Therapeutics and Improved Mechanistic Understanding

Guest Editors:

Dr. Stephanie Duguez
Faculty of Life and Health Sciences, School of Mecidine, Centre of Personalised Medicine, Ulster University, Coleraine, UK

Prof. Dr. Pierre Francois Pradat
Laboratoire d'Imagerie Biomédicale, Sorbonne Universités, CNRS, INSERM, Paris, France

Prof. Dr. Julie Dumonceaux
NIHR Biomedical Research Centre, Great Ormond Street Institute of Child Health, Great Ormond Street Hospital NHS Trust, University College London, London WC1N 1EH, UK

Deadline for manuscript submissions:
closed (15 August 2023)

mdpi.com/si/101065

Message from the Guest Editors

Advancing research for neuromuscular and neurodegenerative diseases requires a coordinated effort between clinicians, scientists, patients and their families, and other stakeholders. This collaboration drives the collection of samples and the direction of clinical investigation, and combined with recent progress in terms of genetic and genomic analysis has enabled the research community to make real gains towards improvements in patient care.

The identification of different groups and subgroups of patients affected by a specific disease pushes the scientific community to move toward personalised/stratified therapeutic strategies. Deciphering the cascade of mechanisms being affected in each subgroup improves our understanding of a given disease and helps us to identify biomarkers and therapeutic strategies.

This Special Issue is dedicated to recent research progress in neuromuscular and neurodegenerative diseases, with a focus on biomarkers, clinical indicators, mechanisms explaining or contributing to irreversible cell loss and therapeutic strategies.

Up-to-date original research papers, communications and reviews will be considered.

Special Issue

Editor-in-Chief

Prof. Dr. David Alan Rizzieri
1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.
Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us